How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

17,001 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. TB/HIV co-infections and associated factors among patients on directly observed treatment short course in Northeastern Ethiopia: a 4 years retrospective study Full Text available with Trip Pro

TB/HIV co-infections and associated factors among patients on directly observed treatment short course in Northeastern Ethiopia: a 4 years retrospective study Human immunodeficiency virus (HIV) and tuberculosis (TB) are the leading independent global causes of death among patients with infectious diseases. Additionally, due to the shared immune defense mechanisms, they are the leading cause of co-morbidities globally. However, little information was found regarding the proportion of TB/HIV co (...) -infection in the study area. Thus, this study determined the proportion and associated factors of TB/HIV co-infection.All TB patients treated from January/2011 to December/2014 were included in this study. Data were collected from three health centers namely; Kobo, Robit and Gobiye. Data were entered, cleared, and analyzed using SPSS version 20. Frequency, percentage, median and range were used to present the data. To assess the associated factors, logistic regression was employed.Of the total 990 TB

2015 BMC research notes

162. Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia. Full Text available with Trip Pro

Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia. In HIV-infected adults in sub-Saharan Africa, asymptomatic cryptococcal antigenemia at the time of antiretroviral therapy (ART) initiation is associated with more than 20% increased mortality. Provisional recommendations for treatment of asymptomatic cryptococcal antigenemia are neither well substantiated nor feasible in many resource-poor settings. After hospitals (...) three CrAg-negative patients, matched for ART start date, for every CrAg-positive patient who had been identified and treated with the 4-week intensive fluconazole course. The primary outcome was 6-month mortality in CrAg-positive and CrAg-negative groups.Mortality of CrAg-positive HIV-infected adults who received short-course fluconazole was noninferior to CrAg-negative adults. At 6 months, 16 of 18 CrAg-positive and 46 of 54 CrAg-negative patients were alive [88.9% versus 85.1%, -3.9% absolute

2015 AIDS

163. Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France

Hepatitis (Inserm-ANRS): Life-event survey observational survey among migrants in France Additional relevant MeSH terms: Layout table for MeSH terms Hepatitis Hepatitis A HIV Infections Hepatitis, Chronic Hepatitis B Hepatitis B, Chronic Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Lentivirus Infections Retroviridae Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases (...) Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2015 Clinical Trials

164. 90-90-90 - Charting a steady course to end the paediatric HIV epidemic. Full Text available with Trip Pro

90-90-90 - Charting a steady course to end the paediatric HIV epidemic. The new "90-90-90" UNAIDS agenda proposes that 90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90% of all people receiving antiretroviral therapy will have viral suppression by 2020. By focusing on children, the global community is in the unique position of realizing an end to the paediatric HIV epidemic.Despite (...) treatment to children, adolescents and families. The road to an AIDS-free generation will require bridging the gaps in HIV services and addressing the particular needs of children across the developmental spectrum from infancy through adolescence. To reach the ambitious new targets, innovations and service improvements will need to be rapidly escalated at each step along the prevention-treatment cascade.Charting a successful course to reach the 90-90-90 targets will require sustained political

2015 Journal of the International AIDS Society

165. A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses

A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government

2015 Clinical Trials

166. Microbial Translocation and Inflammation Occur in Hyperacute Immunodeficiency Virus Infection and Compromise Host Control of Virus Replication Full Text available with Trip Pro

Microbial Translocation and Inflammation Occur in Hyperacute Immunodeficiency Virus Infection and Compromise Host Control of Virus Replication Within the first three weeks of human immunodeficiency virus (HIV) infection, virus replication peaks in peripheral blood. Despite the critical, causal role of virus replication in determining transmissibility and kinetics of progression to acquired immune deficiency syndrome (AIDS), there is limited understanding of the conditions required to transform (...) abundance of CD4+CCR5+ T cell targets of virus replication, and T cell activation. To test whether increasing gastrointestinal permeability to cause microbial translocation would amplify viremia, we treated two SIV-infected macaque 'elite controllers' with a short-course of dextran sulfate sodium (DSS)-stimulating a transient increase in microbial translocation and a prolonged recrudescent viremia. Altogether, our data implicates translocating microbes as amplifiers of immunodeficiency virus replication

2016 PLoS pathogens

167. Post-exposure HIV prophylaxis

who may have been occupationally or sexually exposed to HIV. Once exposed to HIV, there may be a brief period before the infection is established, during which ART may successfully prevent viral replication. Pinto LA, Landay AL, Berzofsky JA, et al. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Am J Med. 1997;102:21-24. http://www.ncbi.nlm.nih.gov/pubmed/9845492?tool=bestpractice.com Spira AI, Marx PA, Patterson BK, et (...) al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med. 1996;183:215-225. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192425/ http://www.ncbi.nlm.nih.gov/pubmed/8551225?tool=bestpractice.com PEP should be given as soon as possible following exposure; a 28-day course of treatment is recommended. Fisher M, Briggs E, Cresswell F, et al. UK guideline for the use of post-exposure prophylaxis

2018 BMJ Best Practice

168. Knowledge of HIV and Related Best Practices Among Non-HIV Specific Health Care Providers

, knowledge, and attitudes of human immunodeficien - cy virus screening among adolescents. Journal of Pediatrics 2013;163(6):1711-5. 7. Hughes AK. HIV knowledge and at- titudes among providers in aging: results from a national survey. AIDS Patient Care & STDs 2011;25(9):539-45. 8. Watkins S, Gray J. Human immu- nodeficiency virus/acquired immune deficiency syndrome: a survey of the knowledge, attitudes, and beliefs of Texas registered nurses in the 21st century. Journal for Nurses in Staff Development (...) intervention called SHIP (Sexual Health in Practice) was introduced to improve knowledge and practices among general practitioners (GPs) in relation to sexually transmitted 12. Levison J, Williams LT, Moore A, McFarlane J, Davila JA. Educating health professionals in obstetrics and gynecol- ogy regarding rapid human immunode- ficiency virus (HIV) testing in labor and delivery: A local initiative. Maternal & Child Health Journal 2012;16(9):1748-53. 13. Pillay TD, Mullineux J, Smith CJ, Matthews P

2015 Ontario HIV Treatment Network

169. Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions Full Text available with Trip Pro

Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 (...) March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions

2013 American Heart Association

170. Canadian HIV Pregnancy Planning Guidelines

Standards Association guidelines for infection control when handling HIV-positive materials and use additional procedures available for the processing of HIV-positive sperm to ensure the preparation of a virus-free sample (III-A). 35. Potentially infectious samples should be processed in a separate laboratory or dedicated area with separate equipment within the main laboratory to reduce the risk of HIV contamination (III-A). 36. Potentially infectious gametes and embryos should be stored (...) Canadian HIV Pregnancy Planning Guidelines No. 354-Canadian HIV Pregnancy Planning Guidelines - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 40, Issue 1, Pages 94–114 No. 354-Canadian HIV Pregnancy Planning Guidelines x Mona Loutfy , MD, MPH (Principal Author) Toronto, ON x V. Logan Kennedy , RN (Principal Author) Toronto, ON x Vanessa Poliquin , MD (Principal Author) Winnipeg, MB x Frederick Dzineku , MD (Principal

2018 Society of Obstetricians and Gynaecologists of Canada

171. Vaccination of HIV infected children

– 13-valent pneumococcal conjugate vaccine Hib/MenC - Haemophilus influenzae type b and Neisseria meningitidis capsular group C conjugate vaccine MenC - meningococcal capsular group C conjugate vaccine 4CMenB – multicomponent meningococcal capsular group B protein vaccine LAIV – live attenuate influenza vaccine MMR – measles, mumps, rubella vaccine HPV – human papilloma virus vaccine MenACWY – quadrivalent meningococcal capsular groups A, C, W and Y conjugate vaccine Hep A&B – combined hepatitis (...) years old (females & males) Cervical cancer caused by human papillomavirus (HPV) types 16 &18; genital warts caused by types 6 & 11 HPV x 3 doses (0, 1, 6 months) Gardasil Upper arm 14 years old (school year 9) Tetanus, diphtheria and polio Meningococcal groups A, C, W, Y disease Hepatitis A and B dTaP/IPV (check MMR status) MenACWY Hep A and B, booster dose or primary course (if previously unimmunised) Revaxis Nimenrix or Menveo Twinrix or Ambirix Upper arm Upper arm Upper arm Notes: 1. All infants

2018 The Children's HIV Association

172. HIV

contact us via jon.brassey@tripdatabase.com Top results for hiv 1. HIV infection and AIDS HIV infection and AIDS - NICE CKS Clinical Knowledge Summaries Share HIV infection and AIDS - Summary The Human Immunodeficiency Virus ( HIV ) is a retrovirus that preferentially infects and destroys cells of the immune system, in particular the CD4 cells (a class of T lymphocyte, also known as T helper cells). There are 2 main types of HIV : HIV -1 (the predominant type in the UK) is highly virulent and is found (...) Management in Australia has developed specific clinical guidance on the topic of when to start antiretroviral therapy in people with HIV . Key considerations concerning the issue 2011 9. Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection ( HIV /TBL) Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection ( HIV /TBL) - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes

2018 Trip Latest and Greatest

173. Efavirenz/Emtricitabine/Tenofovir disoproxil - HIV

Environmental Risk Assessment GC-HS Gas Chromatography head space HDPE High Density Polyethylene HIV Human Immunodeficiency Virus HBV Hepatitis B Virus HPLC High performance liquid chromatography ICH International Conference on Harmonisation of Technical Requirements IR Infrared KF Karl Fischer titration LDPE Low Density Polyethylene Ph. Eur. European Pharmacopoeia RMP Risk Management Plan T max Time of maximum observed plasma concentration; if it occurs at more than one time point, Tmax was defined (...) Krka is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of 5 times the ULN, intenuption or discontinuation of treatment must be considered. • Advice to monitor the liver enzymes of patients treated with other medicinal products associated with liver toxicity. • Warning that reports of hepatic failure have

2018 European Medicines Agency - EPARs

174. Bictegravir / emtricitabine / tenofovir alafenamide / fumarate (Biktarvy) - HIV Infections

substance: Bictegravir / Emtricitabine / Tenofovir Alafenamide International Non-proprietary Name/Common Name: Bictegravir / Emtricitabine / Tenofovir Alafenamide Pharmaco-therapeutic group (ATC Code): Direct acting antivirals, antivirals for treatment of HIV infections, combinations (J05AR) Therapeutic indication(s): Biktarvy is indicated for the treatment of adults infected with human immunodeficiency virus 1 (HIV 1) without present or past evidence of viral resistance to the integrase inhibitor class (...) Practice GEN elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (coformulated; Genvoya®) GI gastrointestinal GLSM geometric least-squares mean GS-9883 bictegravir HBeAb hepatitis B e antibody HBeAg hepatitis B e antigen HBsAb hepatitis B surface antibody HBsAg hepatitis B surface antigen HBV hepatitis B virus HCV hepatitis C virus HDPE High Density Polyethylene HIV human immunodeficiency virus HIV-1 human immunodeficiency virus type 1 HLA human leukocyte antigen HPLC High performance liquid

2018 European Medicines Agency - EPARs

175. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life

. • A negative serological test in children who have had a positive HIV RNA PCR test does not exclude ongoing HIV infection. • A detailed history of any possible previous ART given to the child and/or mother (or other likely source of infec- tion) should be documented. • The genotypic HIV resistance pro?le should be docu- mented at baseline. • The human leucocyte antigen (HLA) B*5701 genotype shouldbecon?rmednegativebeforeusingabacavir(ABC). • Clinical assessment should be carried out 3-4-monthly in children (...) infants at low risk of HIV transmission (maternal VL 100000 copies/ml); • in asymptomatic children aged 1–3 years irrespective of immune status and VL; • in sexually active adolescents, to minimize the risk of onward transmission; • in the presence of any signi?cant HIV-related clinical symptoms; • in hepatitis B virus (HBV) coinfection irrespective of immune status. 6. Which ART regimen to start as ?rst-line therapy • Children should start effective (at least three drugs) ART, usually a dual

2018 The Children's HIV Association

176. Preparing HIV-infected children and adolescents for travel

, Grabar S, Gordien E, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr. 2008;49(3):272-5. 7. Crisinel PA, Posfay-Barbe KM, Aebi C, et al. Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus-infected children living in Switzerland. Clin Vaccine Immunol. 2012;19(11):1751-7. 8. Crane HM, Dhanireddy S, Kim HN, et al. Hepatitis A vaccination among human immuno- deficiency (...) . Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2000;30(1):218. 15. WHO. Vaccines and vaccination against yellow fever: WHO Position Paper. June 2013. http://www.who.int/wer/2013/wer8827.pdf?ua=1. 16. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48(5):659-66. 20 17. Staples JE, Bocchini JA, Jr., Rubin L

2018 The Children's HIV Association

177. HIV postexposure prophylaxis-in-pocket: long-term follow-up of individuals with low-frequency, high-risk HIV exposures. (Abstract)

, and were followed at regular intervals. Demographic and clinical data was collected with a standardized form.In total, 79 patients were initiated on PIP as a primary HIV prevention modality and followed for a mean duration of 14.8 months combining for a total of 97.3 patient-years. Twenty-one (26.6%) patients used their PIP, and 32 courses of PIP were taken during the study period. Transitions between HIV prevention modalities included 13 (16.5%) patients who transitioned from PrEP to PIP, and 22 (27.8 (...) %) patients who transitioned from PIP to PrEP. No HIV seroconversions were detected during the course of this study.PIP is helpful HIV prevention modality for individuals with a low frequency of high-risk HIV exposures.

2020 AIDS

178. Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV

antiretroviral medications are taken by HIV-negative people prior to exposure to the virus to prevent infection. Once-daily oral tenofovir/emtricitabine, as a fixed dose combination tablet, has been licensed and available for use as PrEP in Ireland since 2016. Policy provision for PrEP is contained in the National Sexual Health Strategy 2015–2020, with Priority Action 3 calling for ‘the appropriate use of antiretroviral therapy in HIV prevention’. A PrEP programme provides PrEP medication along with holistic (...) to uncertainty in the parameters. PrEP effectiveness was the main driver of cost-effectiveness in the model. ? The mean number of people expected to join the programme in year one is 1,705 people (95% CI: 617 to 3,452) based on model calibration to the observed number who enrolled in Scotland’s national programme. On average, 173 HIV infections are estimated to be averted over the course of the first five years in the base case analysis. ? In the first year, PrEP medications alone are estimated to cost €1.1m

2019 Health Information and Quality Authority

179. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis

British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019) Guideline Development Group: Cara Saxon (Lead Author), Anne Edwards, Riina Rautemaa- Richardson, Caroline Owen, Bavithra Nathan, Bret Palmer, Clare Wood, Humera Ahmed, Sameena Ahmad, Patient Representatives, Mark FitzGerald (CEG Editor) Clinical Effectiveness Group (...) (CEG), British Association for Sexual Health and HIV (BASHH) NEW IN THE 2019 GUIDELINES Terminology: • The new guidelines refer to ‘acute’ and ‘recurrent’ vulvovaginal candidiasis (VVC) and no longer use the terms ‘uncomplicated’ and ‘complicated’ VVC; the new definitions are felt to be more reflective of how women with VVC typically present to clinical services and are subsequently managed • The elements of complicated VVC where single dose treatments are not always appropriate are still covered

2019 British Association for Sexual Health and HIV

180. Maintaining and improving quality of care within HIV clinical services

and human rights gaps remain: key populations are underserved, experience persistent stigma and discrimination and are subject to criminalization, violence and other human rights abuses (2). To address these gaps and reach global targets, HIV programmes must establish and maintain systems for ensuring a high level of quality in service delivery, within the framework of universal health coverage and supported by national quality policies and strategies. Three seminal 2018 publications (1,3,4) have (...) , district and facility levels and are people-centred. Delivery of quality services depends on all the building blocks of health systems, including optimized management, funding, human resources for health, information systems and procurement of high-quality drugs, laboratory supplies and commodities. In accordance with the 2016 WHO consolidated HIV treatment guidelines (7), quality HIV services should: • provide people-centred care; • offer safe, acceptable and appropriate clinical and non- clinical

2019 World Health Organisation HIV Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>